Tocilizumab antibody | AbD21338_hIgG1

100% Secure


Human anti Tocilizumab:HRP

Anti-tocilizumab antibody is a recombinant, neutralizing anti-idiotypic antibody in fully human IgG1 format, suitable for bioanalytical assays for tocilizumab and biosimilars. It is recommended as detection antibody in a PK bridging ELISA and as a reference standard in an ADA bridging ELISA.

Human anti Tocilizumab

Anti-tocilizumab antibody is a recombinant, neutralizing anti-idiotypic antibody in fully human IgG1 format, suitable for bioanalytical assays for tocilizumab and biosimilars. It is recommended as detection antibody in a PK bridging ELISA and as a reference standard in an ADA bridging ELISA.

Product Type
Monoclonal Antibody
Clone
AbD21338_hIgG1
Isotype
IgG1
Product CodeApplicationsDatasheetMSDSPack SizeList PriceQuantity
HCA253P E 0.1 mg
HCA253 E 0.1 mg
Human Anti-Tocilizumab Antibody, clone AbD21338 is a paratope specific, anti-idiotypic antibody that binds to free tocilizumab but not to human Interleukin-6 Receptor (IL-6R) or the drug/IL-6R complex. The antibody can be used to measure the levels of tocilizumab and biosimilar products in bioanalytical and patient monitoring assays.

Clone AbD21338_hIgG1 is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a surrogate positive control or calibrator (high affinity) in an anti-drug antibody (ADA) assay. Additionally it can be used to develop a pharmacokinetic (PK) bridging assay to measure free drug. This antibody is recommended as the detection antibody, paired with Anti-Tocilizumab Antibody clone AbD21362 (HCA252) in monovalent Fab format as the capture antibody.

Tocilizumab (RoActemra/Actemra) is a humanized IgG1/kappa monoclonal antibody approved for the treatment of moderate to severe rheumatoid arthritis and for the treatment of systemic juvenile idiopathic arthritis. The therapeutic antibody is directed against IL-6R and acts by blocking the binding of IL-6R (both the soluble form, sIL-6R, and the membrane bound form, mIL-6R) to IL-6, thus impeding the pro-inflammatory properties of this cytokine.

View a summary of all anti-tocilizumab antibodies

Product Details

Product Form
Human IgG1 antibody (kappa light chain) selected from the HuCAL® phage display library and expressed in a human cell line. Conjugated to horseradish peroxidase (HRP) - liquid.
Product Form
Human IgG1 antibody (kappa light chain) selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid.
Preparation
Purified IgG prepared by affinity chromatography on Protein A
Preparation
Purified IgG prepared by affinity chromatography on Protein A
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Preservative Stabilisers
0.01% Thiomersal
Preservative Stabilisers
0.01% Thiomersal
Immunogen
Tocilizumab
Affinity
The monovalent intrinsic affinity of this antibody was measured as KD=0.1 nM by real time, label-free molecular interaction analysis on immobilized tocilizuimab.
Approx. Protein Concentrations
IgG concentration 0.1 mg/ml
Approx. Protein Concentrations
Antibody concentration 0.5 mg/ml

Storage Information

Storage
Store at -70oC.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody.
Storage
Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use
Guarantee
12 months from date of despatch
Guarantee
12 months from date of despatch

More Information

Acknowledgements
Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.
Actemra® and RoActemra® are registered trademarks of Hoffman-La Roche and Chugai Pharmaceuticals co., Ltd.
Acknowledgements
Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.
Actemra® and RoActemra® are registered trademarks of Hoffman-La Roche and Chugai Pharmaceuticals co., Ltd.
Licensed Use
For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
Regulatory
For research purposes only

Applications of Tocilizumab antibody

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
ELISA
ELISA
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Technical Advice
Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
Technical Advice
Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
ELISA
This product may be used in a direct ELISA or as a detection reagent in a bridging ELISA together with HCA252 as the capture reagent.
Protocol: PK bridging ELISA to measure free drug
ELISA
This product may be used in a direct ELISA or as a detection reagent in a bridging ELISA together with HCA252 as the capture reagent.
Protocol: PK bridging ELISA to measure free drug
This antibody is fully human and can be used as a reference standard in an ADA assay.
Protocol: ADA bridging ELISA

Useful Reagents Available

Description Product Code Pack Size Applications List Price Quantity
Hispec Assay Diluent BUF049A 50 ml E IY
Human anti Tocilizumab HCA252 0.1 mg E*
Human anti Tocilizumab HCA254 0.1 mg E
Human anti Tocilizumab HCA255 0.1 mg E
Human anti Tocilizumab HCA256 0.1 mg E
Human anti Tocilizumab HCA257 0.1 mg E
Hispec Assay Diluent BUF049A 50 ml E IY
Human anti Tocilizumab HCA252 0.1 mg E*
Human anti Tocilizumab HCA254 0.1 mg E
Human anti Tocilizumab HCA255 0.1 mg E
Human anti Tocilizumab HCA256 0.1 mg E
Human anti Tocilizumab HCA257 0.1 mg E
LYNX Rapid HRP Antibody Conjugation Kit LNK002P 3 Conjugations For 400µg Antibody CJ
Mouse anti Human IgG (Fc) CH2 Domain:HRP MCA647P 0.2 mg C* E
Op-in to our ecommunications and set your preferences to start receiving resources, protocols, product updates, special offers, and more.